Efficacy and tolerability of Ziprasidone vs. Clozapine in the treatment of dually diagnosed (DD-) patients with schizophrenia and cannabis use disorder: A randomised study - Ziprasidone vs. Clozapine for schizophrenia ans cannabis use disorder

Department of Psychiatry and Psychotherapy (Cologne)0 个研究点目标入组 50 人开始时间: 2005年8月23日最近更新: 2012年3月19日

适应症

试验速览

暂无简介。

•1.Patients with schizophrenia, schizophreniform or schizoaffective disorder according to DSM-IV (295.xx) and ICD-10 (F20, F23.2, F25) as well as cannabis abuse or dependence according to DSM-IV (305.20; 304.30) and ICD-10 (F12.1, F12.2)
•2.Written informed consent
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•1.Further relevant neuropsychiatric disorders
•2.Prominent (acute) positive symptoms at the timepoint of inclusion
•3.Previous treatments with ziprasidone or clozapine with significant side effects
•4.No availability of a family member or significant other for the collateral interviews of the follow-up evaluations
•5.No compliance with the requirements of the study / lack of or questionable capability of giving informed consent

发起方

Department of Psychiatry and Psychotherapy (Cologne)